Icu Medical director Elisha Finney sells $83,352 in shares

Published 20/05/2025, 16:58
Icu Medical director Elisha Finney sells $83,352 in shares

Elisha W. Finney, a director at ICU Medical Inc. (NASDAQ:ICUI), a medical technology company with a market capitalization of $3.4 billion, recently sold 600 shares of the company’s common stock. According to InvestingPro data, while ICU Medical isn’t currently profitable, analysts expect positive earnings in 2025. The transaction, which took place on May 19, 2025, was executed at a price of $138.92 per share, totaling $83,352. Following this sale, Finney holds 3,252 shares of ICU Medical. The shares were sold at the exact price disclosed, as noted in the filing. InvestingPro analysis indicates the stock is currently slightly undervalued, with analysts setting price targets between $175 and $200. Get access to detailed financial metrics and 6 additional ProTips with an InvestingPro subscription.

In other recent news, ICU Medical reported impressive financial results for the first quarter of 2025, with earnings and revenue figures exceeding analysts’ expectations. The company announced an adjusted earnings per share (EPS) of $1.72, surpassing the forecasted $1.27, and reported revenue of $599 million, above the anticipated $567.08 million. ICU Medical also experienced a 10% revenue growth in constant currency terms, driven by strong performance in its Consumables and Infusion Systems segments. Despite the positive earnings report, Needham maintained a Hold rating on ICU Medical’s stock, citing the company’s current valuation as a factor. The firm’s recent joint venture with Otsuka Pharmaceutical (TADAWUL:2070) Factory for IV Solutions was completed on May 1, 2025, with expectations to mitigate tariff impacts partially through favorable currency exchange rates and internal strategies. Additionally, ICU Medical expanded its stock incentive plan, increasing the number of shares available for issuance to align the interests of employees and directors with shareholders. The company continues to focus on growth and profitability while navigating challenges such as tariff impacts and currency fluctuations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.